{{Rsnum
|rsid=743554
|Gene=GALK1
|Chromosome=17
|position=75758167
|Orientation=plus
|GMAF=0.1373
|Gene_s=GALK1,ITGB4
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 73.4 | 23.4 | 3.1
| HCB | 95.2 | 4.8 | 0.0
| JPT | 97.7 | 2.3 | 0.0
| YRI | 58.1 | 35.5 | 6.5
| ASW | 0.0 | 0.0 | 0.0
| CHB | 95.2 | 4.8 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}
{{PMID|18550570}} [[microRNA]] 749 Swedish incident [[breast cancer]] cases with detailed clinical data and up to 15 years of follow-up together with 1493 matched controls. The strongest association was between the [[rs743554]](T) allele of the [[ITGB4]] gene and estrogen receptor negative (ER-) tumors (odds ratio 2.09, CI: 1.19-3.67) and worse survival compared to the wild type genotype carriers (hazard ratio [HR] 2.11, CI: 1.21-3.68). The poor survival was significantly associated with the aggressive tumour characteristics: high grade, lymph node metastasis and high stage.

{{ neighbor
| rsid = 871443
| distance = 745
}}

{{PMID Auto
|PMID=19290790
|Title=MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}